Citations (119)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Brandon N. VanderVeen, Thomas D. Cardaci, Sierra J. McDonald, Sarah S. Madero, Christian A. Unger, Brooke M. Bullard, Reilly T. Enos, Kandy T. Velázquez, Jason L. Kubinak, Daping Fan & E. Angela Murphy. (2022) Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice. Cancer Biology & Therapy 23:1, pages 1-15.
Read now
Read now
Laureen A. Lammers, Roos Achterbergh, Ron A.A. Mathôt & Johannes A. Romijn. (2020) The effects of fasting on drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 79-85.
Read now
Read now
Cene Skubic, Živa Drakulić & Damjana Rozman. (2018) Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opinion on Drug Metabolism & Toxicology 14:8, pages 831-841.
Read now
Read now
Carlemi Calitz, Josias H. Hamman, Stephen J. Fey, Krzysztof Wrzesinski & Chrisna Gouws. (2018) Recent advances in three-dimensional cell culturing to assess liver function and dysfunction: from a drug biotransformation and toxicity perspective. Toxicology Mechanisms and Methods 28:5, pages 369-385.
Read now
Read now
Santosh Kumar Sreevatsav Adiraju, Kiran Shekar, John F. Fraser, Maree T. Smith & Sussan Ghassabian. (2018) Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy. Drug Metabolism Reviews 50:2, pages 109-124.
Read now
Read now
Chunlan Zheng, Xiufen Hu, Li Zhao, Minhui Hu & Feng Gao. (2017) Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?. Drug Design, Development and Therapy 11, pages 2957-2968.
Read now
Read now
Rolf Teschke & Gaby Danan. (2017) Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 425-438.
Read now
Read now
Enoch Cobbina & Fatemeh Akhlaghi. (2017) Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metabolism Reviews 49:2, pages 197-211.
Read now
Read now
Nathalie K. Zgheib & Robert A. Branch. (2017) Drug metabolism and liver disease: a drug–gene–environment interaction. Drug Metabolism Reviews 49:1, pages 35-55.
Read now
Read now
Minhui Hu, Chunlan Zheng & Feng Gao. (2016) Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug Design, Development and Therapy 10, pages 3983-3994.
Read now
Read now
Articles from other publishers (109)
Michael Murray. (2023) Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents. Clinical Pharmacokinetics 62:10, pages 1365-1392.
Crossref
Crossref
Xiaofei Xin, Jingjing Li, Wantao Wu, Pengbo Zhao, Yang Yang, Ying Zhu, Lianjie Ren, Chao Qin & Lifang Yin. (2023) ROS-scavenging nanomedicine for “multiple crosstalk” modulation in non-alcoholic fatty liver disease. Biomaterials Science 11:10, pages 3709-3725.
Crossref
Crossref
Chieri Fujino, Taiki Kuzu, Yukine Kubo, Kurumi Hayashi, Satoshi Ueshima & Toshiya Katsura. (2023) Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models. Biopharmaceutics & Drug Disposition.
Crossref
Crossref
Markus Koponen, Jaana Rysä, Anna-Kaisa Ruotsalainen, Olli Kärkkäinen & Risto O. Juvonen. (2023) Western Diet Decreases Hepatic Drug Metabolism in Male LDLr−/−ApoB100/100 Mice. Journal of Nutrition and Metabolism 2023, pages 1-12.
Crossref
Crossref
Geoffrey Y. Sasaki, Yael Vodovotz, Zhongtang Yu & Richard S. Bruno. (2022) Catechin Bioavailability Following Consumption of a Green Tea Extract Confection Is Reduced in Obese Persons without Affecting Gut Microbial-Derived Valerolactones. Antioxidants 11:12, pages 2490.
Crossref
Crossref
Giovanni Tarantino, Mauro Cataldi & Vincenzo Citro. (2022) Could Alcohol Abuse and Dependence on Junk Foods Inducing Obesity and/or Illicit Drug Use Represent Danger to Liver in Young People with Altered Psychological/Relational Spheres or Emotional Problems?. International Journal of Molecular Sciences 23:18, pages 10406.
Crossref
Crossref
Mei-Ling Li, Chun-Yin Huang, Szu-Han Chen, Chia-Ni Lee & Hsien-Tsung Yao. (2022)
Citrus depressa
Hayata peel ameliorates nonalcoholic fatty liver and modulates the activity of hepatic drug-metabolizing enzymes and transporters in rats fed a high-fat diet
. Food & Function 13:6, pages 3353-3367.
Crossref
Crossref
Rawan Alraish, Sebastian G. Wicha, Otto R. Frey, Anka C. Roehr, Johann Pratschke, Martin Stockmann, Tilo Wuensch & Magnus Kaffarnik. (2022) Liver function, quantified by the LiMAx test, as a predictor for the clinical outcome of critically ill patients treated with linezolid. Technology and Health Care 30:2, pages 309-321.
Crossref
Crossref
Jacqueline G. Gerhart, Stephen Balevic, Jaydeep Sinha, Eliana M. Perrin, Jian Wang, Andrea N. Edginton & Daniel Gonzalez. (2022) Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations. Frontiers in Pharmacology 13.
Crossref
Crossref
Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad & Arun J. Sanyal. (2022) Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. Diabetes & Metabolism 48:2, pages 101281.
Crossref
Crossref
Camilo Rey-Bedon, Peony Banik, Aslihan Gokaltun, O. Hofheinz, Martin.L. Yarmush, M. Korkut Uygun & O. Berk Usta. (2022) CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. Biomedicine & Pharmacotherapy 146, pages 112377.
Crossref
Crossref
Sri Riyati Sugiarto, Madhu Page-Sharp, Jocelyn J. Drinkwater, Wendy A. Davis, Sam Salman & Timothy M.E. Davis. (2022) Pharmacokinetic properties of the antimalarial combination therapy artemether–lumefantrine in normal-weight, overweight and obese healthy male adults. International Journal of Antimicrobial Agents 59:1, pages 106482.
Crossref
Crossref
Michael D. Wiese, Ashley S. Meakin, Tamara J. Varcoe, Jack R.T. Darby, Ousseynou Sarr, Patti Kiser, Emma L. Bradshaw, Timothy R.H. Regnault & Janna L. Morrison. (2021) Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. Life Sciences 287, pages 120133.
Crossref
Crossref
Sarah Kim, Sora Choi, Moumita Dutta, Jeffrey O. Asubonteng, Marianne Polunas, Michael Goedken, Frank J. Gonzalez, Julia Yue Cui & Maxwell A. Gyamfi. (2021) Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature. Biochemical Pharmacology 193, pages 114698.
Crossref
Crossref
Mark Shapses, Lin Tang, Austin Layne, Andrea Beri & Yaron Rotman. (2021) Fatty Liver Is an Independent Risk Factor for Delayed Recovery from Anesthesia. Hepatology Communications 5:11, pages 1848-1859.
Crossref
Crossref
Zhao-Chun Chi. (2021) Research status and progress of drug induced liver injury. World Chinese Journal of Digestology 29:16, pages 915-925.
Crossref
Crossref
David A. Kukla & Salman R. Khetani. (2021) Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine. Seminars in Liver Disease 41:03, pages 368-392.
Crossref
Crossref
Agostino Di Ciaula, Federico Carbone, Harshitha Shanmugham, Emilio Molina-Molina, Leonilde Bonfrate, Stefano Ministrini, Fabrizio Montecucco & Piero Portincasa. (2021) Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver. European Journal of Internal Medicine 89, pages 56-64.
Crossref
Crossref
Melisa Kozaczek, Walter Bottje, Diyana Albataineh & Reza Hakkak. (2021) Effects of Short- and Long-Term Soy Protein Feeding on Hepatic Cytochrome P450 Expression in Obese Nonalcoholic Fatty Liver Disease Rat Model. Frontiers in Nutrition 8.
Crossref
Crossref
Daniel Gonzalez & Jaydeep Sinha. (2021) Pediatric Drug‐Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. The Journal of Clinical Pharmacology 61:S1.
Crossref
Crossref
Karina L. Raikhelson, Elina A. Kondrashina & Ekaterina V. Pazenko. (2021) Mixed steatohepatitis: more questions than answers (part 2). Terapevticheskii arkhiv 93:4, pages 516-520.
Crossref
Crossref
Qian Yu, Yann-yin Lee, Zheng-yun Xia, Emily C. Liong, Jia Xiao & George L. Tipoe. (2020) S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation. European Journal of Nutrition 60:2, pages 961-973.
Crossref
Crossref
Mohamed F. Abdallah, André Briend & Gerard Bryan Gonzales. (2021) Aflatoxins and kwashiorkor: A commentary on the association-causation conundrum. Toxicon 190, pages 20-21.
Crossref
Crossref
Yeo-Jung Kwon, Sangyun Shin & Young-Jin Chun. (2021) Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Archives of Pharmacal Research 44:1, pages 63-83.
Crossref
Crossref
Jaydeep Sinha, Stephen B. Duffull, Bruce Green & Hesham S. Al-Sallami. (2020) Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. Current Drug Metabolism 21:10, pages 746-750.
Crossref
Crossref
Jennifer Phillips, Rebecca Preskey, Chris Penfold, Fiona Gordon & Jonathan Tyrrell-Price. (2020) Liver steatosis is a risk factor for hepatotoxicity in inflammatory bowel disease patients treated with azathioprine. European Journal of Gastroenterology & Hepatology 32:10, pages 1390-1394.
Crossref
Crossref
Rohitash Jamwal & Benjamin J. Barlock. (2020) Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals 13:9, pages 222.
Crossref
Crossref
Sebastian Michels, Eugen Zizer, Thomas FE Barth, Anette Wassner, Tanja Fangerau, Daniela Taranu, Franziska Bachhuber, Hayrettin Tumani & Makbule Senel. (2020) Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift®). Multiple Sclerosis and Related Disorders 40, pages 101948.
Crossref
Crossref
Marc Ruoß, Massoud Vosough, Alfred Königsrainer, Silvio Nadalin, Silvia Wagner, Sahar Sajadian, Diana Huber, Zahra Heydari, Sabrina Ehnert, Jan G. Hengstler & Andreas K. Nussler. (2020) Towards improved hepatocyte cultures: Progress and limitations. Food and Chemical Toxicology 138, pages 111188.
Crossref
Crossref
Jaydeep Sinha, Stephen B. Duffull, Bruce Green & Hesham S. Al-Sallami. (2019) Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. Clinical Pharmacokinetics 59:4, pages 475-483.
Crossref
Crossref
Hideaki Note, Hiroki Tsubouchi, Yukiya Wada, Hirotoshi Murase, Miki Nakano, Ai Muramatsu, Takahiko Sugino & Mahito Kawano. (2020) A case of propofol related infusion syndrome within the limited dose制限内投与量で発症したプロポフォール注入症候群の1例. Journal of the Japanese Society of Intensive Care Medicine 27:1, pages 41-42.
Crossref
Crossref
John Nowicki & Joseph E. Pizzorno. 2020. Textbook of Natural Medicine. Textbook of Natural Medicine
1600
1604.e3
.
Chao Hou, Wenwen Feng, Shan Wei, Yulin Wang, Xiaoyi Xu, Jin Wei, Ziliang Ma, Yongsheng Du, Jialin Guo, Yu He, Fanyun Kong, Renxian Tang & Kuiyang Zheng. (2019) Bioinformatics Analysis of Key Differentially Expressed Genes in Nonalcoholic Fatty Liver Disease Mice Models. Gene Expression 19:1, pages 25-35.
Crossref
Crossref
Gregory H. Underhill & Salman R. Khetani. (2019)
Emerging trends in modeling human liver disease
in vitro
. APL Bioengineering 3:4.
Crossref
Crossref
Osama Y. Alshogran. (2019) Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Current Drug Metabolism 20:8, pages 633-645.
Crossref
Crossref
Carolina TorresGeorgina MancinelliJose Cordoba-ChaconNavin ViswakarmaKarla CastellanosSam GrimaldoSandeep KumarDaniel PrincipeMatthew J. DormanRonald McKinneyEmilio Hirsch, David DawsonHidayatullah G. Munshi, Ajay RanaPaul J. Grippo. (2019) p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proceedings of the National Academy of Sciences 116:29, pages 14724-14733.
Crossref
Crossref
Carlemi Calitz, Josias H. Hamman, Stephen J. Fey, Alvaro M. Viljoen, Chrisna Gouws & Krzysztof Wrzesinski. (2019) A sub-chronic Xysmalobium undulatum hepatotoxicity investigation in HepG2/C3A spheroid cultures compared to an in vivo model. Journal of Ethnopharmacology 239, pages 111897.
Crossref
Crossref
Elaine M. Hylek & Frank A. Anania. (2019) Oral Anticoagulants in Liver Disease. Journal of the American College of Cardiology 73:25, pages 3309-3311.
Crossref
Crossref
Raúl J. Andrade, Guruprasad P. Aithal, Einar S. Björnsson, Neil Kaplowitz, Gerd A. Kullak-Ublick, Dominique Larrey & Tom H. Karlsen. (2019) EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology 70:6, pages 1222-1261.
Crossref
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clozapine Handbook. The Clozapine Handbook
204
223
.
B. Goubaux. (2019) Anestesia del paciente adulto obeso. EMC - Anestesia-Reanimación 45:1, pages 1-12.
Crossref
Crossref
Asmita Pant, Elizabeth A. Rondini & Thomas A. Kocarek. (2019) Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells. Toxicology and Applied Pharmacology 365, pages 61-70.
Crossref
Crossref
B. Goubaux. (2019) Gestione anestetica del paziente adulto obeso. EMC - Anestesia-Rianimazione 24:1, pages 1-11.
Crossref
Crossref
Julien Allard, Dounia Le Guillou, Karima Begriche & Bernard Fromenty. 2019. Drug-induced Liver Injury. Drug-induced Liver Injury
75
107
.
Jesse G. Meyer, Samir Softic, Nathan Basisty, Matthew J. Rardin, Eric Verdin, Bradford W. Gibson, Olga Ilkayeva, Christopher B. Newgard, C. Ronald Kahn & Birgit Schilling. (2018) Temporal dynamics of liver mitochondrial protein acetylation and succinylation and metabolites due to high fat diet and/or excess glucose or fructose. PLOS ONE 13:12, pages e0208973.
Crossref
Crossref
Sofia G. Verstraete, Janet M. Wojcicki, Emily R. Perito & Philip Rosenthal. (2018) Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003–2010. Environmental Health 17:1.
Crossref
Crossref
Xilin Li, Zemin Wang & James E. Klaunig. (2018) Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease. Toxicology 410, pages 199-213.
Crossref
Crossref
Arnaud Tête, Isabelle Gallais, Muhammad Imran, Martine Chevanne, Marie Liamin, Lydie Sparfel, Simon Bucher, Agnès Burel, Normand Podechard, Brice M.R. Appenzeller, Bernard Fromenty, Nathalie Grova, Odile Sergent & Dominique Lagadic-Gossmann. (2018) Mechanisms involved in the death of steatotic WIF-B9 hepatocytes co-exposed to benzo[a]pyrene and ethanol: a possible key role for xenobiotic metabolism and nitric oxide. Free Radical Biology and Medicine 129, pages 323-337.
Crossref
Crossref
Laureen A. Lammers, Roos Achterbergh, Johannes A. Romijn & Ron A. A. Mathôt. (2018) Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5′-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. European Journal of Drug Metabolism and Pharmacokinetics 43:6, pages 751-767.
Crossref
Crossref
Shubha Ghosh Dastidar, Ganapathy Jagatheesan, Petra Haberzettl, Jasmit Shah, Bradford G. Hill, Aruni Bhatnagar & Daniel J. Conklin. (2018)
Glutathione
S
-transferase P deficiency induces glucose intolerance via JNK-dependent enhancement of hepatic gluconeogenesis
. American Journal of Physiology-Endocrinology and Metabolism 315:5, pages E1005-E1018.
Crossref
Crossref
Fernando Bessone, Melisa Dirchwolf, María Agustina Rodil, María Valeria Razori & Marcelo G. Roma. (2018) Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Alimentary Pharmacology & Therapeutics 48:9, pages 892-913.
Crossref
Crossref
Muhammad Suleman Khan & Michael S. Roberts. (2018) Challenges and innovations of drug delivery in older age. Advanced Drug Delivery Reviews 135, pages 3-38.
Crossref
Crossref
Elaina M. Maldonado, Ciarán P. Fisher, Dawn J. Mazzatti, Amy L. Barber, Marcus J. Tindall, Nicholas J. Plant, Andrzej M. Kierzek & J. Bernadette Moore. (2018) Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease. npj Systems Biology and Applications 4:1.
Crossref
Crossref
Ann-Yae Na, Jung Jae Jo, Oh Kwang Kwon, Riya Shrestha, Pil Joung Cho, Kyu Min Kim, Sung Hwan Ki, Tae Hee Lee, Tae Won Jeon, Tae Cheon Jeong & Sangkyu Lee. (2018) Investigation of nonalcoholic fatty liver disease-induced drug metabolism by comparative global toxicoproteomics. Toxicology and Applied Pharmacology 352, pages 28-37.
Crossref
Crossref
James E. Klaunig, Xilin Li & Zemin Wang. (2018) Role of xenobiotics in the induction and progression of fatty liver disease. Toxicology Research 7:4, pages 664-680.
Crossref
Crossref
Satoshi Kamata, Naoya Fujino, Mitsuhiro Yamada, Ken Grime, Satoshi Suzuki, Chiharu Ota, Yukiko Tando, Yoshinori Okada, Akira Sakurada, Masafumi Noda, Yasushi Matsuda, Hisatoshi Sugiura & Masakazu Ichinose. (2018) Expression of cytochrome P450 mRNAs in Type II alveolar cells from subjects with chronic obstructive pulmonary disease. Pharmacology Research & Perspectives 6:3, pages e00405.
Crossref
Crossref
A. Rolle, S. Paredes, L.I. Cortínez, B.J. Anderson, N. Quezada, S. Solari, F. Allende, J. Torres, D. Cabrera, V. Contreras, J. Carmona, C. Ramírez, A.M. Oliveros & M. Ibacache. (2018) Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. British Journal of Anaesthesia 120:5, pages 969-977.
Crossref
Crossref
Simon Bucher, Arnaud Tête, Normand Podechard, Marie Liamin, Dounia Le Guillou, Martine Chevanne, Cédric Coulouarn, Muhammad Imran, Isabelle Gallais, Morgane Fernier, Quentin Hamdaoui, Marie-Anne Robin, Odile Sergent, Bernard Fromenty & Dominique Lagadic-Gossmann. (2018) Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Scientific Reports 8:1.
Crossref
Crossref
Norman Tanner, Lisa Kubik, Claudia Luckert, Maria Thomas, Ute Hofmann, Ulrich M. Zanger, Linda Böhmert, Alfonso Lampen & Albert Braeuning. (2018) Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells. Drug Metabolism and Disposition 46:4, pages 326-335.
Crossref
Crossref
M. Dallio, M. Masarone, S. Errico, A. G. Gravina, C. Nicolucci, R. Di Sarno, L. Gionti, C. Tuccillo, M. Persico, P. Stiuso, N. Diano, C. Loguercio & A. Federico. (2018) Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Alimentary Pharmacology & Therapeutics 47:6, pages 826-837.
Crossref
Crossref
Wen-Chang Chang, Da-Wei Huang, Jou-An Chen, Yu-Fang Chang, James Swi-Bea Wu & Szu-Chuan Shen. (2018)
Protective effect of
Ruellia tuberosa
L. extracts against abnormal expression of hepatic detoxification enzymes in diabetic rats
. RSC Advances 8:38, pages 21596-21605.
Crossref
Crossref
Gregory H. Underhill & Salman R. Khetani. (2018) Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. Cellular and Molecular Gastroenterology and Hepatology 5:3, pages 426-439.e1.
Crossref
Crossref
Peerut Chienwichai, Supachai Topanurak, Onrapak Reamtong, Usa Boonyuen, Suwalee Worakhunpiset & Prapin Tharnpoophasiam. (2018) Effects of low bisphenol A concentration on protein expression profiles in an in vitro model of non-alcoholic fatty liver disease. Molecular & Cellular Toxicology 14:1, pages 61-70.
Crossref
Crossref
Chase P. Monckton & Salman R. Khetani. 2018. Drug-Induced Liver Toxicity. Drug-Induced Liver Toxicity
213
248
.
L H Lang, K Parekh, B Y K Tsui & M Maze. (2017) Perioperative management of the obese surgical patient. British Medical Bulletin 124:1, pages 135-155.
Crossref
Crossref
Jose Ignacio Vargas, Juan Pablo Arab, Fernando Bessone, Maria Isabel Lucena, Raul J. Andrade & Marco Arrese. (2017) Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. Current Hepatology Reports 16:4, pages 286-292.
Crossref
Crossref
Lan Wang, Qiong-Hui Huang, Yong-Xian Li, Yan-Feng Huang, Jian-Hui Xie, Lie-Qiang Xu, Yao-Xing Dou, Zi-Ren Su, Hui-Fang Zeng & Jian-Nan Chen. (2017) Protective effects of silymarin on triptolide-induced acute hepatotoxicity in rats. Molecular Medicine Reports.
Crossref
Crossref
Sebastian G. Wicha, Otto R. Frey, Anka C. Roehr, Johann Pratschke, Martin Stockmann, Rawan Alraish, Tilo Wuensch & Magnus Kaffarnik. (2017) Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. International Journal of Antimicrobial Agents 50:4, pages 557-563.
Crossref
Crossref
Laureen A. Lammers, Roos Achterbergh, Ron H. N. van Schaik, Johannes A. Romijn & Ron A. A. Mathôt. (2017) Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clinical Pharmacokinetics 56:10, pages 1231-1244.
Crossref
Crossref
Maria Margalef, Zara Pons, Lisard Iglesias-Carres, Francisca Isabel Bravo, Begoña Muguerza & Anna Arola-Arnal. (2017) Flavanol plasma bioavailability is affected by metabolic syndrome in rats. Food Chemistry 231, pages 287-294.
Crossref
Crossref
V Pierre, CK Johnston, BC Ferslew, KLR Brouwer & D Gonzalez. (2017) Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. CPT: Pharmacometrics & Systems Pharmacology 6:5, pages 331-339.
Crossref
Crossref
Joseph A. Cichocki, Shinji Furuya, Kranti Konganti, Yu-Syuan Luo, Thomas J. McDonald, Yasuhiro Iwata, Weihsueh A. Chiu, David W. Threadgill, Igor P. Pogribny & Ivan Rusyn. (2017) Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice. Journal of Pharmacology and Experimental Therapeutics 361:1, pages 17-28.
Crossref
Crossref
Matthew D. Davidson, David A. Kukla & Salman R. Khetani. (2017) Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integrative Biology 9:8, pages 662-677.
Crossref
Crossref
R. Sane & M. Sinz. 2017. Drug Metabolism in Diseases. Drug Metabolism in Diseases
1
19
.
Dorothy A Kieffer, Roy J Martin & Sean H Adams. (2016) Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys. Advances in Nutrition 7:6, pages 1111-1121.
Crossref
Crossref
Nagaraj M. Kulkarni, Sandeep Malampati, Mahamad Yunnus A. Mahat, S. Chandrasekaran, J. Raghul, Ansar Ali Khan, Uma Maheswari Krishnan & Shridhar Narayanan. (2016) Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metabolism and Personalized Therapy 31:3, pages 165-171.
Crossref
Crossref
Sung-Joon Cho, Sang-Bum Kim, Hyun-Jong Cho, Saeho Chong, Suk-Jae Chung, Il-Mo Kang, Jangik Ike Lee, In-Soo Yoon & Dae-Duk Kim. (2016) Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. Journal of Agricultural and Food Chemistry 64:27, pages 5598-5606.
Crossref
Crossref
Richard D. Beger & Thomas J. Flynn. (2016) Pharmacometabolomics in drug safety and drug-exposome interactions. Metabolomics 12:7.
Crossref
Crossref
Matthew D. Davidson, Kimberly R. Ballinger & Salman R. Khetani. (2016) Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Scientific Reports 6:1.
Crossref
Crossref
Banrida Wahlang, Russell A. Prough, K. Cameron Falkner, Josiah E. Hardesty, Ming Song, Heather B. Clair, Barbara J. Clark, J. Christopher States, Gavin E. Arteel & Matthew C. Cave. (2016) Polychlorinated Biphenyl-Xenobiotic Nuclear Receptor Interactions Regulate Energy Metabolism, Behavior, and Inflammation in Non-alcoholic-Steatohepatitis. Toxicological Sciences 149:2, pages 396-410.
Crossref
Crossref
Sang Won Park, Jung-Woo Kang & Sun-Mee Lee. (2016) The role of heme oxygenase-1 in drug metabolizing dysfunction in the alcoholic fatty liver exposed to ischemic injury. Toxicology and Applied Pharmacology 292, pages 30-39.
Crossref
Crossref
Emine B. Yalcin, Supriya R. Kulkarni, Angela L. Slitt & Roberta King. (2016) Bisphenol A sulfonation is impaired in metabolic and liver disease. Toxicology and Applied Pharmacology 292, pages 75-84.
Crossref
Crossref
Kamisha L. Johnson-Davis & Amitava Dasgupta. 2016. Clinical Challenges in Therapeutic Drug Monitoring. Clinical Challenges in Therapeutic Drug Monitoring
245
260
.
Syed Tabish R. Zaidi. 2016. Drug Dosing in Obesity. Drug Dosing in Obesity
1
12
.
O. KUČERA, H. LOTKOVÁ, O. SOBOTKA & Z. ČERVINKOVÁ. (2015) The Effect of D-Galactosamine on Lean and Steatotic Rat Hepatocytes in Primary Culture. Physiological Research, pages S637-S646.
Crossref
Crossref
Vilma E. Ortiz & Jean Kwo. (2015) Obesity: physiologic changes and implications for preoperative management. BMC Anesthesiology 15:1.
Crossref
Crossref
Maria Margalef, Zara Pons, Lisard Iglesias-Carres, Francisca Isabel Bravo, Begoña Muguerza & Anna Arola-Arnal. (2015) Lack of Tissue Accumulation of Grape Seed Flavanols after Daily Long-Term Administration in Healthy and Cafeteria-Diet Obese Rats. Journal of Agricultural and Food Chemistry 63:45, pages 9996-10003.
Crossref
Crossref
Ann-Kathrin Stoldt, Michael Derno, Gerd Nürnberg, Joachim M. Weitzel, Winfried Otten, Alexander Starke, Siegfried Wolffram & Cornelia C. Metges. (2015) Effects of a 6-wk intraduodenal supplementation with quercetin on energy metabolism and indicators of liver damage in periparturient dairy cows. Journal of Dairy Science 98:7, pages 4509-4520.
Crossref
Crossref
John D. Clarke & Nathan J. Cherrington. (2015) Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacology & Therapeutics 151, pages 99-106.
Crossref
Crossref
Laureen A. Lammers, Roos Achterbergh, Emmely M. de Vries, F. Samuel van Nierop, Heinz-Josef Klümpen, Maarten R. Soeters, Anita Boelen, Johannes A. Romijn & Ron A. A. Mathôt. (2015) Short-Term Fasting Alters Cytochrome P450–Mediated Drug Metabolism in Humans. Drug Metabolism and Disposition 43:6, pages 819-828.
Crossref
Crossref
Sang Won Park, Jung-Woo Kang & Sun-Mee Lee. (2015) Role of Kupffer cells in ischemic injury in alcoholic fatty liver. Journal of Surgical Research 194:1, pages 91-100.
Crossref
Crossref
April D. Lake, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald G. Robertson, Michael D. Reily, Lois D. Lehman-McKeeman, Richard R. Vaillancourt & Nathan J. Cherrington. (2014) Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 47:3, pages 603-615.
Crossref
Crossref
Makoto ShiraiMiho MatsuokaToshihiko MakinoKiyonori KaiMunehiro TeranishiWataru Takasaki. (2015) Hepatic glutathione contributes to attenuation of thioacetamide-induced hepatic necrosis due to suppression of oxidative stress in diet-induced obese mice. The Journal of Toxicological Sciences 40:4, pages 509-521.
Crossref
Crossref
S. AlGhamdi, V. Leoncikas, K. E. Plant & N. J. Plant. (2015) Synergistic interaction between lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced cytotoxicity and cellular oxidative stress: implications for acute and chronic care of obese cancer patients. Toxicology Research 4:6, pages 1479-1487.
Crossref
Crossref
Michael Kyriakides, Rhiannon N. Hardwick, Zhaosheng Jin, Michael J. Goedken, Elaine Holmes, Nathan J. Cherrington & Muireann Coen. (2014) Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat. Toxicological Sciences 142:1, pages 105-116.
Crossref
Crossref
Robert N. Schuck, Weibin Zha, Matthew L. Edin, Artiom Gruzdev, Kimberly C. Vendrov, Tricia M. Miller, Zhenghong Xu, Fred B. Lih, Laura M. DeGraff, Kenneth B. Tomer, H. Michael Jones, Liza Makowski, Leaf Huang, Samuel M. Poloyac, Darryl C. Zeldin & Craig R. Lee. (2014) The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease. PLoS ONE 9:10, pages e110162.
Crossref
Crossref
Neville Campbell, Stanley Ikezi & Shawn Kumar. (2014) Acute Pain Management in the Obese Patient. Topics in Pain Management 30:2, pages 1-10.
Crossref
Crossref
Banrida Wahlang, Ming Song, Juliane I. Beier, K. Cameron Falkner, Laila Al-Eryani, Heather B. Clair, Russell A. Prough, Tanasa S. Osborne, David E. Malarkey, J. Christopher States & Matthew C. Cave. (2014) Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicology and Applied Pharmacology 279:3, pages 380-390.
Crossref
Crossref
Banrida Wahlang, K. Cameron Falkner, Heather B. Clair, Laila Al-Eryani, Russell A. Prough, J. Christopher States, Denise M. Coslo, Curtis J. Omiecinski & Matthew C. Cave. (2014) Human Receptor Activation by Aroclor 1260, a Polychlorinated Biphenyl Mixture. Toxicological Sciences 140:2, pages 283-297.
Crossref
Crossref
John D. Clarke, Rhiannon N. Hardwick, April D. Lake, Andrew J. Lickteig, Michael J. Goedken, Curtis D. Klaassen & Nathan J. Cherrington. (2014) Synergistic interaction between genetics and disease on pravastatin disposition. Journal of Hepatology 61:1, pages 139-147.
Crossref
Crossref
John D. Clarke, Rhiannon N. Hardwick, April D. Lake, Mark J. Canet & Nathan J. Cherrington. (2014) Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression. Journal of Pharmacology and Experimental Therapeutics 348:3, pages 452-458.
Crossref
Crossref
M. James Lopez & Jacob L. Bilhartz. 2014. Diseases of the Liver in Children. Diseases of the Liver in Children
371
388
.
Emine B. Yalcin, Vijay More, Karissa L. Neira, Zhenqiang James Lu, Nathan J. Cherrington, Angela L. Slitt & Roberta S. King. (2013) Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers. Drug Metabolism and Disposition 41:9, pages 1642-1650.
Crossref
Crossref
Rhiannon N. Hardwick, Daniel W. Ferreira, Vijay R. More, April D. Lake, Zhenqiang Lu, Jose E. Manautou, Angela L. Slitt & Nathan J. Cherrington. (2013) Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 41:3, pages 554-561.
Crossref
Crossref
Banrida Wahlang, Juliane I. Beier, Heather B. Clair, Heather J. Bellis-Jones, K. Cameron Falkner, Craig J. McClain & Matt C. Cave. (2012) Toxicant-associated Steatohepatitis. Toxicologic Pathology 41:2, pages 343-360.
Crossref
Crossref
Makoto SHIRAI, Shingo ARAKAWA, Hiroaki MIIDA, Takuya MATSUYAMA, Junzo KINOSHITA, Toshihiko MAKINO, Kiyonori KAI & Munehiro TERANISHI. (2013) Thioacetamide-induced Hepatocellular Necrosis Is Attenuated in Diet-induced Obese Mice. Journal of Toxicologic Pathology 26:2, pages 175-186.
Crossref
Crossref
Amitava Dasgupta. 2012. Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring. Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
1
30
.
Amitava Dasgupta. 2012. Therapeutic Drug Monitoring. Therapeutic Drug Monitoring
1
29
.
C. S. Pitchumoni, C. S. Pitchumoni & C. S. Pitchumoni. 2012. Geriatric Gastroenterology. Geriatric Gastroenterology
399
407
.